RU2010148785A - Фармацевтическое средство для стимуляции функциональной регенерации поврежденной ткани - Google Patents

Фармацевтическое средство для стимуляции функциональной регенерации поврежденной ткани Download PDF

Info

Publication number
RU2010148785A
RU2010148785A RU2010148785/10A RU2010148785A RU2010148785A RU 2010148785 A RU2010148785 A RU 2010148785A RU 2010148785/10 A RU2010148785/10 A RU 2010148785/10A RU 2010148785 A RU2010148785 A RU 2010148785A RU 2010148785 A RU2010148785 A RU 2010148785A
Authority
RU
Russia
Prior art keywords
protein
cell
secrets
vector
dna encoding
Prior art date
Application number
RU2010148785/10A
Other languages
English (en)
Russian (ru)
Inventor
Кацуто ТАМАИ (JP)
Кацуто ТАМАИ
Такехико ЯМАЗАКИ (JP)
Такехико ЯМАЗАКИ
Такенао ТИНО (JP)
Такенао ТИНО
Ясуфуми КАНЕДА (JP)
Ясуфуми КАНЕДА
Original Assignee
Дженомикс Ко., Лтд. (Jp)
Дженомикс Ко., Лтд.
Осака Юниверсити (Jp)
Осака Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженомикс Ко., Лтд. (Jp), Дженомикс Ко., Лтд., Осака Юниверсити (Jp), Осака Юниверсити filed Critical Дженомикс Ко., Лтд. (Jp)
Publication of RU2010148785A publication Critical patent/RU2010148785A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0393Animal model comprising a reporter system for screening tests

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
RU2010148785/10A 2008-04-30 2009-04-30 Фармацевтическое средство для стимуляции функциональной регенерации поврежденной ткани RU2010148785A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008119324 2008-04-30
JP2008-119324 2008-04-30

Publications (1)

Publication Number Publication Date
RU2010148785A true RU2010148785A (ru) 2012-06-10

Family

ID=41255155

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010148785/10A RU2010148785A (ru) 2008-04-30 2009-04-30 Фармацевтическое средство для стимуляции функциональной регенерации поврежденной ткани

Country Status (10)

Country Link
US (1) US20110097309A1 (enExample)
EP (1) EP2301560A4 (enExample)
JP (3) JP5814549B2 (enExample)
KR (1) KR20110027665A (enExample)
CN (1) CN102076351A (enExample)
AU (1) AU2009240885A1 (enExample)
BR (1) BRPI0911436A2 (enExample)
CA (1) CA2722906A1 (enExample)
RU (1) RU2010148785A (enExample)
WO (1) WO2009133940A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2649069C2 (ru) * 2012-10-25 2018-04-02 Дженомикс Ко., Лтд. Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
US12421498B2 (en) 2017-12-01 2025-09-23 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
US12428458B2 (en) 2018-02-08 2025-09-30 StemRIM Inc. Therapeutic agent for psoriasis

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2722852A1 (en) * 2008-04-30 2009-11-05 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
US20110097309A1 (en) * 2008-04-30 2011-04-28 Katsuto Tamai Pharmaceutical Agent for Promoting the Functional Regeneration of Damaged Tissue
US9919010B2 (en) * 2008-04-30 2018-03-20 Genomix Co., Ltd. Method for collecting functional cells in vivo with high efficiency
EP2494977B1 (en) * 2009-10-28 2018-06-13 Genomix Co., Ltd. Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood
JP5852773B2 (ja) 2010-06-01 2016-02-03 ピアス株式会社 骨髄間葉系幹細胞の誘引剤の製造方法、骨髄間葉系幹細胞の誘引方法、及び、骨髄間葉系幹細胞の誘引剤を製造するための使用
ES2788394T3 (es) 2011-04-26 2020-10-21 Stemrim Inc Péptido para inducir regeneración de tejido y uso del mismo
AU2013335684B2 (en) 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
CN108367068B (zh) * 2015-09-14 2021-08-03 拉瓦尔大学 用于治疗白血病的抗-s100a8
EP3556378B1 (en) 2017-01-27 2025-03-12 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
SG11201909851SA (en) 2017-04-25 2019-11-28 Shionogi & Co Peptide for inducing regeneration of tissue, and use thereof
CN110709506A (zh) * 2017-07-18 2020-01-17 株式会社资生堂 间充质干细胞导引剂
EP3756679A1 (en) * 2019-06-28 2020-12-30 Université de Genève Compositions for use in the treatment of insulin deficiency conditions
CN111494423B (zh) * 2020-04-22 2022-01-25 上海市东方医院(同济大学附属东方医院) 一种干细胞组合物及其应用和干细胞滴液
CN115058388A (zh) * 2022-03-14 2022-09-16 福建医科大学附属协和医院 间充质干细胞创面修复优势功能亚群及其鉴定和应用
CN120837666A (zh) * 2025-09-22 2025-10-28 中国人民解放军军事科学院军事医学研究院 靶向巨噬细胞s100a9蛋白在肝纤维化治疗中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
JP3018313B2 (ja) * 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
EP1114862A3 (de) * 1999-11-17 2003-08-06 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
WO2001062895A2 (en) * 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20040191246A1 (en) * 2003-02-26 2004-09-30 Connelly Patrick R. Process for in vivo treatment of specific biological targets in bodily fluid
AU2002304710A1 (en) * 2001-04-30 2002-11-11 Switch Biotech Ag Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
US20020197633A1 (en) * 2001-05-09 2002-12-26 Jones Brian C. Evaluation of ultraviolet radiation damage to skin using new gene markers, methods and compositions related thereto
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
CN100484569C (zh) * 2001-11-19 2009-05-06 协和发酵工业株式会社 将多潜能干细胞从组织中流通到外周血的药物
AU2003228099A1 (en) * 2002-07-03 2004-01-23 Centro Cardiologico Monzino S.P.A.-Irccs Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
ATE427758T1 (de) * 2002-07-05 2009-04-15 Univ Laval Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
US20070154529A1 (en) * 2003-01-03 2007-07-05 Alcedo Biotech Gmbh Uses of dna binding proteins
WO2004084928A1 (en) * 2003-03-28 2004-10-07 UNIVERSITé LAVAL S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
WO2006008779A1 (en) * 2004-07-20 2006-01-26 Provincia Italiana Della Congregazione Dei Figli Dell'immacolata Concezione-Istituto Dermopatico Dell'immacolata Use of hmgb1 for wound healing
KR100593397B1 (ko) * 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 p 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
WO2006047820A1 (en) * 2004-11-01 2006-05-11 Newsouth Innovations Pty Limited Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation
KR20090078304A (ko) * 2006-10-30 2009-07-17 가부시키가이샤 제노믹스 손상 조직의 기능적 재생 촉진용 의약
CA2722852A1 (en) * 2008-04-30 2009-11-05 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
US20110097309A1 (en) * 2008-04-30 2011-04-28 Katsuto Tamai Pharmaceutical Agent for Promoting the Functional Regeneration of Damaged Tissue
US9919010B2 (en) * 2008-04-30 2018-03-20 Genomix Co., Ltd. Method for collecting functional cells in vivo with high efficiency

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2649069C2 (ru) * 2012-10-25 2018-04-02 Дженомикс Ко., Лтд. Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease
US12421498B2 (en) 2017-12-01 2025-09-23 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
US12428458B2 (en) 2018-02-08 2025-09-30 StemRIM Inc. Therapeutic agent for psoriasis
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization

Also Published As

Publication number Publication date
KR20110027665A (ko) 2011-03-16
JPWO2009133940A1 (ja) 2011-09-01
JP5960735B2 (ja) 2016-08-02
EP2301560A4 (en) 2012-05-09
CN102076351A (zh) 2011-05-25
JP5814549B2 (ja) 2015-11-17
US20110097309A1 (en) 2011-04-28
AU2009240885A2 (en) 2011-01-27
CA2722906A1 (en) 2009-11-05
JP2014139177A (ja) 2014-07-31
AU2009240885A1 (en) 2009-11-05
JP2016104790A (ja) 2016-06-09
BRPI0911436A2 (pt) 2016-07-12
WO2009133940A1 (ja) 2009-11-05
EP2301560A1 (en) 2011-03-30

Similar Documents

Publication Publication Date Title
RU2010148785A (ru) Фармацевтическое средство для стимуляции функциональной регенерации поврежденной ткани
EA201270571A1 (ru) Человеческие il-23-антигенсвязывающие белки
EA201170635A1 (ru) Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
CY1117655T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
CY1116728T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
EA201690994A1 (ru) Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком
EA202090739A1 (ru) Белки, связывающие антиген созревания в-клеток
EA201490379A1 (ru) Варианты белков axmi205 и способы их применения
EA201892774A1 (ru) Антитела
EP4249036A3 (en) Methods and products for nucleic acid production and delivery
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
EA201490374A1 (ru) Ген пестицида axmi279 и способы его применения
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
EA201171006A1 (ru) Вариантные гены axmi-r1 дельта-эндотоксина и способы их применения
EA201071323A1 (ru) Axmi-115, axmi-113, axmi-005, axmi-163, axmi-184 инсектицидные белки и способы их применения
RU2021132734A (ru) Химерные рецепторы антигена, нацеленные на psca
ZA200800517B (en) Transplastomic plants expressing lumen-targeted protein
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
WO2013126590A3 (en) Pharmaceutical composition comprising cd34+ cells
EA201400401A1 (ru) Биокомпозит для регенерации поврежденных тканей и органов, набор для изготовления биокомпозита и способ лечения
ATE395924T1 (de) Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen
EA201490995A1 (ru) Использование фо-ти для усиления мобилизации и пролиферации стволовых клеток
EA201691192A1 (ru) Гены токсинов axmi477, axmi482, axmi486 и axmi525 и способы их применения
MX2019009896A (es) Gen insecticida variante axmi115 y metodos para utilizarlo.
MY151330A (en) Systems and method for separating proteins from connective tissue

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20131108